ライフサイエンスコーパス: lymphedema

1 can be utilized for effective management of lymphedema.

2 ecessary axillary lymph node dissections and lymphedema.

3 stases, but is associated with a 14% risk of lymphedema.

4 ene cause Hennekam syndrome, a primary human lymphedema.

5 n promising results in preclinical models of lymphedema.

6 ting their possible involvement in secondary lymphedema.

7 of VEGFR3 has been reported to cause primary lymphedema.

8 ique provided a fresh hope for patients with lymphedema.

9 s immediately applicable to reduce secondary lymphedema.

10 oma formation was increased in patients with lymphedema.

11 with a frameshift mutation also have primary lymphedema.

12 atic vessel function in 5 of 6 patients with lymphedema.

13 ed lymphatic maps in patients with secondary lymphedema.

14 th symptomatic pathologic conditions such as lymphedema.

15 and normal limbs of patients with secondary lymphedema.

16 lymphatic function that result in inherited lymphedema.

17 l that manifested lymphatic hyperplasia with lymphedema.

18 ng lymphatic development result in inherited lymphedema.

19 gents as potential therapy for some forms of lymphedema.

20 ise did not result in increased incidence of lymphedema.

21 ngs, such as radiation or associated chronic lymphedema.

22 as used to ascertain factors associated with lymphedema.

23 ics within the axilla and its use may reduce lymphedema.

24 patients had claims indicating treatment of lymphedema.

25 d symptoms can be early signs of progressing lymphedema.

26 e presence of measured and patient-perceived lymphedema.

27 there remains a clinically relevant risk of lymphedema.

28 recautions if they had measured or perceived lymphedema.

29 phedema development and treating established lymphedema.

30 and 2% reported chronically moderate/severe lymphedema.

31 ients reporting no arm swelling had measured lymphedema.

32 are significant risk factors for developing lymphedema.

33 are significant risk factors for perceiving lymphedema.

34 oderate/severe lymphedema than women with no lymphedema.

35 esia, arm morbidity and range of motion, and lymphedema.

36 or those with arm symptoms without diagnosed lymphedema.

37 She did not develop postsurgical lymphedema.

38 with 5% and 16%, respectively, with measured lymphedema.

39 -gestation after development of interstitial lymphedema.

40 s with a FOXC2 mutation, including 3 without lymphedema.

41 e B4 (LTB4) in the molecular pathogenesis of lymphedema.

42 lay a key role in mediating the pathology of lymphedema.

43 yed hypoplastic facial lymphatics and severe lymphedema.

44 institution were screened prospectively for lymphedema.

45 reatment risk, prevention, and management of lymphedema.

46 al manifestation of lymphatic malfunction is lymphedema.

47 breast reconstruction impacts development of lymphedema.

48 phangiogenesis in clinical settings, such as lymphedema.

49 tic endothelial cells at the early stages of lymphedema.

50 9-cis RA significantly prevents postsurgical lymphedema.

51 s treated for breast cancer and screened for lymphedema.

52 ent to limit the development of postsurgical lymphedema.

53 ing lymph nodes for the purpose of relieving lymphedema.

54 atalogue of human GATA2 mutations results in lymphedema.

55 es of bilateral lower extremity inflammatory lymphedema.

56 se of bilateral lower extremity inflammatory lymphedema.

57 h both cancer-related and non-cancer-related lymphedema.

58 that VLNT may help alleviate the severity of lymphedema.

59 , vascular/lymphatic (venous thrombosis 25%, lymphedema 11%), sensorineural hearing loss 76%, miscarr

60 for 3 years, 23% reported no more than mild lymphedema, 12% reported moderate/severe lymphedema, and

61 one results in a significantly lower rate of lymphedema 5 years postoperatively.

62 cute pneumonitis (1.2% vs. 0.2%, P=0.01) and lymphedema (8.4% vs. 4.5%, P=0.001).

63 Secondary lymphedema, a life-long complication of cancer treatment

64 In breast cancer survivors at risk for lymphedema, a program of slowly progressive weight lifti

65 ctive formation of lymphatic valves leads to lymphedema, a progressive and debilitating condition for

66 idelines for breast cancer survivors without lymphedema advise against upper body exercise, preventin

67 Lymphedema affects up to 1 in 6 patients who undergo tre

68 Lymphedema after breast cancer is common but mostly mild

69 Postoperative lymphedema after breast cancer surgery is a challenging

70 2.5-fold greater fluid retention and severe lymphedema after inflammation.

71 es may represent a novel means of preventing lymphedema after lymph node resection.

72 an ideal option for patients who suffer from lymphedema after mastectomy and axillary dissection.

73 was to determine the long-term prevalence of lymphedema after SLN biopsy (SLNB) alone and after SLNB

74 uman lymphatic system and reduce the risk of lymphedema after surgery for melanoma and other cancers.

75 Thirty-seven percent of women with mild lymphedema and 68% with moderate/severe lymphedema recei

76 ional analyses to describe the prevalence of lymphedema and arm symptoms and multivariate-adjusted ge

77 Patient-perceived lymphedema and avoidant behaviors were assessed through

78 or lymphatic related diseases, which include lymphedema and cancer.

79 was lower for BrCa survivors with diagnosed lymphedema and for those with arm symptoms without diagn

80 Two larger families cosegregate lymphedema and GJC2 mutation (LOD score = 6.5).

81 ped a highly reproducible model of secondary lymphedema and have demonstrated that 9-cis RA significa

82 to determine what interventions can improve lymphedema and impact HRQOL for BrCa survivors.

83 ng tissue fibrosis, we used a mouse model of lymphedema and inhibited TGF-beta function either system

84 consecutive patients with uni- or bilateral lymphedema and lymph vessel transplants of the lower ext

85 iated with several human diseases, including lymphedema and metastatic spread of cancer.

86 Associations between lymphedema and potential risk factors were examined.

87 aploinsufficiency of GATA2 underlies primary lymphedema and predisposes to acute myeloid leukemia in

88 berger syndrome, a disorder characterized by lymphedema and predisposition to myelodysplastic syndrom

89 deficient in lymphovenous hemostasis exhibit lymphedema and sometimes chylothorax phenotypes indicati

90 tations to include predisposition to primary lymphedema and suggest that complete haploinsufficiency

91 tissue fibrosis and lymphatic dysfunction in lymphedema and that inhibition of Th2 differentiation ma

92 thogenesis of many human diseases, including lymphedema and tumor metastasis.

93 undertaken to examine patient perceptions of lymphedema and use of precautionary behaviors several ye

94 her 15 unrelated microcephalic probands with lymphedema and/or chorioretinopathy identified additiona

95 osomal-dominant microcephaly associated with lymphedema and/or chorioretinopathy.

96 s correlated positively with the severity of lymphedema (and presumed inflammation) in filarial-disea

97 ild lymphedema, 12% reported moderate/severe lymphedema, and 2% reported chronically moderate/severe

98 BrCa survivors, 8.1% self-reported diagnosed lymphedema, and 37.2% self-reported arm symptoms.

99 patients reporting arm swelling had measured lymphedema, and 5% of patients reporting no arm swelling

100 L) among working-age women, the incidence of lymphedema, and associated risk factors.

101 e recently identified to cause microcephaly, lymphedema, and chorioretinal dysplasia (MLCRD) as well

102 e formation in lymphatic collecting vessels, lymphedema, and chylothorax.

103 ts molecular regulation during inflammation, lymphedema, and lymphatic metastasis.

104 utation is associated with immunodeficiency, lymphedema, and myelodysplastic syndrome.

105 incidence of long-term side effects, notably lymphedema, and the procedure is of no therapeutic benef

106 ymphatic development, the pathophysiology of lymphedema, and the role of leukotrienes in lymphedema p

107 nt of various human diseases such as cancer, lymphedema, and tissue allograft rejection.

108 disease, obesity, cancer, and cancer-related lymphedema are highlighted.

109 ue node metastases, axillary recurrence, and lymphedema as measured by volume displacement.

110 surgery were prospectively screened for arm lymphedema as quantified by the weight-adjusted volume c

111 Using mouse models of lymphedema, as well as clinical lymphedema specimens, we

112 The difference between the two groups' lymphedema, assessed by arm measurements at 30 days (P =

113 rger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute mye

114 We sought to determine the risk of lymphedema associated with immediate breast reconstructi

115 pression of several molecules, including the lymphedema-associated transcription factor FOXC2.

116 There was no difference in lymphedema at any time point.

117 Thirteen women had prevalent lymphedema at baseline.

118 005 and 2013 were prospectively screened for lymphedema at our institution, with 22.2 months' median

119 ated in a number of chronic diseases such as lymphedema, atherosclerosis, and cancer.

120 into therapies for conditions as diverse as lymphedema, autoimmunity, and cancer.

121 the economic burden of breast cancer-related lymphedema (BCRL) among working-age women, the incidence

122 and risk of developing breast cancer-related lymphedema (BCRL) in patients who underwent axillary lym

123 nd rate of infections likely associated with lymphedema between a woman with BCRL and a matched contr

124 postoperative recovery between the 2 groups (lymphedema breast reconstruction and breast reconstructi

125 verage operation time was 426 minutes in the lymphedema breast reconstruction group and 391 minutes i

126 ckade prevents initiation and progression of lymphedema by decreasing tissue fibrosis and significant

127 cacy in ameliorating experimental mouse tail lymphedema by enhancing lymphatic vessel regeneration.

128 T cells play a key role in the pathology of lymphedema by promoting tissue fibrosis and inhibiting l

129 iopsy use and 5-year cumulative incidence of lymphedema by race.

130 y account for about one third of all primary lymphedema cases, underscoring the existence of addition

131 implicate it as a candidate gene for primary lymphedema caused by valve defects.

132 dred inheriting a unique autosomal-recessive lymphedema-choanal atresia syndrome.

133 clerosing cholangitis and was diagnosed with lymphedema cholestasis syndrome (LCS).

134 rocephaly and lymphedema from a microcephaly-lymphedema-chorioretinal-dysplasia cohort.

135 ilial forms of primary lymphedema, secondary lymphedema, chylothorax and chylous ascites, lymphatic m

136 resided in the West were more likely to have lymphedema claims than those in the Northeast (OR = 2.05

137 ted as cancer-related and non-cancer-related lymphedema cohorts.

138 reconstruction does not increase the risk of lymphedema compared to mastectomy alone.

139 ociated with a significantly reduced risk of lymphedema compared to no reconstruction.

140 ostsurgical edema and significantly less paw lymphedema compared with vehicle-treated animals at all

141 Of the 654 arms, 83 developed lymphedema, defined as a WAC >/= 10% relative to baselin

142 sive drug, is highly effective in preventing lymphedema development and treating established lymphede

143 e that debilitating and persistent preputial lymphedema develops after a prepuce-sparing penile deglo

144 he prepuce can at times be preserved even if lymphedema develops.

145 s, or lymphatic vessel obstruction can cause lymphedema, disfiguring tissue swelling often associated

146 Because lymphedema distichiasis is believed to be caused by lymp

147 Mutations in the FOXC2 gene cause lymphedema distichiasis, an inherited primary lymphedema

148 genital fibrosis of the extraocular muscles, lymphedema-distichiasis syndrome, neurofibromatosis type

149 As FOXC2 is mutated in lymphedema-distichiasis syndrome, our data also undersco

150 econd row of eyelashes is a feature of human lymphedema-distichiasis syndrome, which is associated wi

151 ranscription factor that is mutated in human lymphedema-distichiasis syndrome.

152 causes congenital lymphatic dysfunction and lymphedema due to defective lymphatic vessel patterning

153 ssociated with a higher probability of later lymphedema (eg, hazard ratio for jewelry too tight = 7.3

154 en genes have already been linked to primary lymphedema, either isolated, or as part of a syndrome.

155 undation for clinical investigations whereby lymphedema etiogenesis and therapies may be interrogated

156 me are strongly linked to a history of fetal lymphedema, evidenced by the presence of neck webbing an

157 r both comparisons) and a lower incidence of lymphedema exacerbations as assessed by a certified lymp

158 ility in the study of diseases as diverse as lymphedema, filariasis, transplant rejection, obesity, a

159 Among the 238 affected women, lymphedema first occurred within 2 years of diagnosis in

160 duals with a combination of microcephaly and lymphedema from a microcephaly-lymphedema-chorioretinal-

161 lymphedema or arm symptoms without diagnosed lymphedema had lower physical and mental HRQOL compared

162 esults with the use of VLNT for treatment of lymphedema have been largely positive, further explorati

163 Patients who suffer from lymphedema have impaired immunity and, as a result, are

164 echanisms by which GATA2 mutations result in lymphedema have not been characterized.

165 C2 are dominantly associated with late-onset lymphedema; however, the precise role of FOXC2 and a clo

166 Arm circumference measurements documented lymphedema in 5% of SLNB alone patients, compared with 1

167 the lifestyle and clinical risk factors for lymphedema in a cohort of patients who underwent bilater

168 roach to the management of treatment-induced lymphedema in cancer survivors.

169 sed as a preventative agent for postsurgical lymphedema in humans.

170 egulation of GATA2, which has been linked to lymphedema in patients with Emberger syndrome.

171 ymphedema distichiasis, an inherited primary lymphedema in which a significant number of patients hav

172 assumption that it would reduce the risk of lymphedema in women with breast cancer.

173 assumption that it would reduce the risk of lymphedema in women with breast cancer.

174 quivalence margin was defined as doubling of lymphedema incidence.

175 s expressed in tissue components affected by lymphedema, including epidermis, lymphatics, and blood v

176 is necessary for the pathological changes of lymphedema, including fibrosis, adipose deposition, and

177 system in edema, genetic aspects of primary lymphedema, infection (cellulitis/erysipelas), Crohn's d

178 olved in many pathological processes such as lymphedema, inflammatory diseases, and tumor metastasis.

179 s that although cellulitis increases risk of lymphedema, ipsilateral blood draws, injections, blood p

180 Lymphedema is a common complication that occurs after br

181 Lymphedema is a complication of cancer treatment occurri

182 Lymphedema is a debilitating condition that often result

183 Secondary lymphedema is a debilitating condition, and genetic fact

184 Lymphedema is a dreaded complication of cancer treatment

185 Primary lymphedema is due to developmental and/or functional def

186 The prevalence and clinical burden of lymphedema is known to be increasing.

187 Lymphedema is the clinical manifestation of defects in l

188 uman analog is mutated in some families with lymphedema, is also highly enriched in a subset of endot

189 to determine whether improvement of filarial lymphedema (LE) by doxycycline is restricted to patients

190 PURPOSE Cancer-related lymphedema (LE) is an incurable condition associated wit

191 uineous family with two children affected by lymphedema, lymphangiectasia and distinct facial feature

192 of pathological tissue changes that occur in lymphedema may be a viable treatment strategy for this d

193 the time of surgery, or have upper extremity lymphedema may be less likely to undergo repeated mammog

194 phatic drainage after injection of MSCs in a lymphedema model indicates that MSCs play a role in lymp

195 We used an experimental murine tail lymphedema model where sustained fluid stasis was genera

196 In a murine lymphedema model, galectin-1(-/-) animals had increased

197 es lymphatic regeneration in an experimental lymphedema model, presenting it as a promising novel the

198 GATA2 mutation is associated with deafness, lymphedema, mononuclear cytopenias, infection, myelodysp

199 e than a quarter of the incidence of primary lymphedema, mostly of inherited forms.

200 ma was low among survivors without diagnosed lymphedema (n = 1,183).

201 following three survivor groups: women with lymphedema (n = 104), women with arm symptoms without di

202 ), women with arm symptoms without diagnosed lymphedema (n = 475), and women without lymphedema or ar

203 we assigned a score indicating the degree of lymphedema (none, mild, or moderate/severe) to each mont

204 s included the incidence of exacerbations of lymphedema, number and severity of lymphedema symptoms,

205 %) of bilateral lower extremity inflammatory lymphedema occurred during the first 120 hours of traini

206 Primary lymphedema occurs as a result of aberrations in the deve

207 ving 141 breast-cancer survivors with stable lymphedema of the arm.

208 ould like to know what she can do to prevent lymphedema on her upcoming flight to Vienna.

209 Lymphedema onset was associated with pronounced infiltra

210 utations, is the key predisposing factor for lymphedema onset.

211 osed lymphedema (n = 475), and women without lymphedema or arm symptoms (n = 708).

212 ultivariate adjustment, women with diagnosed lymphedema or arm symptoms without diagnosed lymphedema

213 and mental HRQOL compared with women without lymphedema or arm symptoms.

214 e impaired immune responses in patients with lymphedema or following lymphatic injury remain unknown.

215 ically tractable system for the treatment of lymphedema or inhibition of tumor metastasis.

216 s that involve the lymphatic system, such as lymphedema or lymphatic metastasis.

217 The impact of lymphedema or related arm symptoms on health-related qua

218 by mycobacterial infection, myelodysplasia, lymphedema, or aplastic anemia that progress to myeloid

219 quent long-term effects (eg, second cancers, lymphedema, osteoporosis).

220 nd, potentially, tumor lymphangiogenesis and lymphedema (pages 993-994).

221 r endogenous AM as a key factor in secondary lymphedema pathogenesis and provided experimental in viv

222 lymphedema, and the role of leukotrienes in lymphedema pathogenesis.

223 ermine the role of inflammatory responses in lymphedema pathology.

224 Lymphedema patients have decreased quality of life and r

225 ovides a basis for future clinical trials in lymphedema patients.

226 ising novel therapeutic agent to treat human lymphedema patients.

227 we have provided a molecular explanation for lymphedema predisposition in a subset of patients with g

228 scribed for women with breast-cancer-related lymphedema, preventing them from obtaining the well-esta

229 e lymphatic vasculature during the course of lymphedema progression.

230 A 52-year old patient presented with lymphedema, protein loosing enteropathy, and sclerosing

231 tion of GJC2 mutations as a cause of primary lymphedema raises the possibility of novel gap-junction-

232 ression analyses were performed to determine lymphedema rates and risk factors.

233 Lymphedema rates are dramatically reduced using ARM when

234 Objective lymphedema rates for SLNB and ALND were 0.8% and 6.5% re

235 We hypothesized that disconcerting lymphedema rates in both sentinel lymph node biopsy (SLN

236 mild lymphedema and 68% with moderate/severe lymphedema received treatment.

237 in a decreased incidence of exacerbations of lymphedema, reduced symptoms, and increased strength.

238 Among the cancer cohort, total lymphedema-related costs per patient, excluding medical

239 Lymphedema-related direct costs were measured for home h

240 in the noncancer cohort; P < .001 for both), lymphedema-related manual therapy (from 35.6% to 24.9%in

241 Rates of cellulitis, use of lymphedema-related manual therapy, outpatient hospital v

242 Because of its morbidity and chronicity, arm lymphedema remains a concerning complication of breast c

243 is limited by the fact that the pathology of lymphedema remains unknown.

244 oportions of women with increasing degree of lymphedema reported symptoms (eg, jewelry too tight, tir

245 Podoconiosis is a tropical lymphedema resulting from long-term barefoot exposure to

246 ompletely characterized, and their effect on lymphedema risk is not known.

247 gs may help to guide patient education about lymphedema risk reduction strategies for those who under

248 ratified by type of axillary surgery, 5-year lymphedema risk was 6.8% in whites undergoing SLNB (HR,

249 Overall, the 5-year cumulative lymphedema risk was 8.2% in whites and 12.3% in blacks (

250 LNB use contributed to racial disparities in lymphedema risk.

251 (P = 0.0324) were associated with increased lymphedema risk.

252 sels: sporadic and familial forms of primary lymphedema, secondary lymphedema, chylothorax and chylou

253 In breast-cancer survivors with lymphedema, slowly progressive weight lifting had no sig

254 ema exacerbations as assessed by a certified lymphedema specialist (14% vs. 29%, P=0.04).

255 se models of lymphedema, as well as clinical lymphedema specimens, we show that lymphatic stasis resu

256 tions in patients with chorioretinopathy and lymphedema suggests that EG5 is involved in the developm

257 ean (+/- SE) time between BrCa diagnosis and lymphedema survey was 8.1 +/- 0.2 years.

258 For all patients with lymphedema symptoms (n = 9), we used a modified lower ab

259 er improvements in self-reported severity of lymphedema symptoms (P=0.03) and upper- and lower-body s

260 ations of lymphedema, number and severity of lymphedema symptoms, and muscle strength.

261 Hennekam lymphangiectasia-lymphedema syndrome (Online Mendelian Inheritance in Man

262 ons that cause the Hennekam lymphangiectasia-lymphedema syndrome syndrome type1.

263 othelial markers and the study of congenital lymphedema syndromes.

264 of lymphatic vessels and valves causes human lymphedema syndromes.

265 times more likely to develop moderate/severe lymphedema than women with no lymphedema.

266 loped bilateral lower extremity inflammatory lymphedema that occurred during the 8(1/2)-week basic tr

267 Lymphedema, the most common lymphatic anomaly, involves

268 sed comparative effectiveness data regarding lymphedema therapeutic interventions have been poor.

269 lity was evaluated in patients with stage II lymphedema (three women; age range, 43-64 years) and in

270 These results have profound implications for lymphedema treatment as topical tacrolimus is FDA-approv

271 led equivalence trial (Physical Activity and Lymphedema trial) in the Philadelphia metropolitan area

272 lysis of data from the Physical Activity and Lymphedema Trial, we examined incident deterioration of

273 Five-year cumulative incidence of lymphedema was 42 (42%) per 100 women.

274 The two-year cumulative incidence of lymphedema was as follows: 4.08% [95% confidence interva

275 At median follow-up of 5 years, lymphedema was assessed in 936 women with clinically nod

276 resthesia, brachial plexus injury (BPI), and lymphedema was available for 821 patients.

277 Lymphedema was defined as 10% or more arm volume increas

278 Lymphedema was induced in the right hind limb after a si

279 Knowledge of lymphedema was low among survivors without diagnosed lym

280 Lymphedema was monitored at baseline and 6 months by mea

281 Lymphedema was more common after SLND + ALND but was sig

282 g our combined injury protocol, postsurgical lymphedema was observed 89% of the time.

283 Lymphedema was observed in 24.1% of the patients in the

284 Secondary lymphedema was prevented when circulating AM levels in A

285 At 1 year, lymphedema was reported subjectively by 13% (37 of 288)

286 group of families with dominantly inherited lymphedema, we identified six probands with unique misse

287 ether AM deficiency predisposes to secondary lymphedema, we used heterozygous adult mice with Adm gen

288 ptoms present before the first occurrence of lymphedema were associated with a higher probability of

289 me since surgery, and having upper extremity lymphedema were associated with lower mammography adhere

290 en previously treated for breast cancer with lymphedema were enrolled from six institutions.

291 Risk factors associated with measured lymphedema were greater body weight (P < .0001), higher

292 Viral infections and lymphedema were more common in individuals with null mut

293 Women with mild lymphedema were more than three times more likely to dev

294 Toxic effects, including lymphedema, were increased in the cohorts receiving comp

295 e characteristic swelling of tissues, called lymphedema, which arises as a consequence of insufficien

296 Patients with lymphedema who received an APCD who were commercially in

297 to demonstrate a significant improvement in lymphedema with decongestive therapy compared with a mor

298 ukemia (AML); and Emberger syndrome (primary lymphedema with MDS).

299 data may underestimate the true incidence of lymphedema, women with BCRL had a greater risk of infect

300 function of lymphatic valves underlies human lymphedema, yet the process of valve morphogenesis is po